Losartan and Simvastatin Inhibit Platelet Activation in Hypertensive Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Diabetic patients also show hypercoagulability and platelet hyperaggregability, with increased levels of platelet activation-markers such as P-selectin (CD62P) and platelet-derived microparticles. We investigated the effects of losartan and simvastatin on circulating levels of platelet activation markers, microparticles, soluble selectins, and soluble cell adhesion molecules in hypertensive and hyperlipidemic patients with or without Type 2 diabetes.
Methods: The subjects included 25 normotensive healthy controls and 41 hypertensive patients. The 41 hypertensive patients were divided into three groups: group A had hypertension and hyperlipidemia (n = 11), group B had hypertension and Type 2 diabetes (n = 14), and group C had hypertension, hyperlipidemia, and diabetes (n = 16). Losartan was administered to all of the patients at a dose of 50 mg/day for 24 weeks. In addition, simvastatin was administered to the hyperlipidemic patients at a dose of 10 mg/day for 24 weeks.
Results: There were significant differences in the levels of CD62P, CD63, PAC-1, platelet microparticles, endothelial microparticles, sE-selectin, and sVCAM-1 between the hypertensive patients and healthy controls. These markers were all significantly increased in hypertensive and hyperlipidemic patients with Type 2 diabetes. In hypertensive patients with diabetes, CD62P, CD63, PAC-1, platelet and endothelial microparticles, and soluble adhesion markers were all decreased by losartan monotherapy. The decrease of each marker in hypertensive and hyperlipidemic patients given combined therapy with losartan plus simvastatin was greater among those with than without Type 2 diabetes. Low-density lipoprotein was decreased significantly by simvastatin and was correlated with CD62P or platelet microparticles in all of the patients.
Conclusion: Administration of losartan plus simvastatin to hypertensive and hyperlipidemic patients with Type 2 diabetes may prevent the development of cardiovascular complications caused by activated platelets and microparticles via another mechanism in addition to reduction of the blood pressure or lipid levels.
- Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten years cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175–1184. CrossRef
- Pugh JA, Medina RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end-stage renal disease: More evidence for a tri-ethnic community. Diabetes 1995;44:1375–1380.
- Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55).Diabetes Care 2001;24:1167–1174.
- Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 1992;41 (Suppl.2):86–91.
- Carmassi F, Morale M, Puccett R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992;67:643–654. CrossRef
- Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994;72:979–984.
- Cominacini L, Pasini AF, Garbin U, et al. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: Possible role of oxidative stress. Diabetologia 1997;40:584–589. CrossRef
- Schafer AI. The hypercoagulable states. Ann Intern Med 1985;102:814–818.
- Frade LJG, de la Calle H, Alava I, Navarro JL, Ceighton LJ, Gaffney PJ. Diabetes as a hypercoagulable state: Its relationship with fibrin fragments and vascular damage. Thromb Res 1987;47:533–540. CrossRef
- Tschope D, Esser J, Schwippert B, et al. Large platelets circulate in an activated state in diabetes. Semin Thromb Haemost 1991;17:433–439.
- Nomura S, Komiyama Y, Miyake T, et al. Amyloid β-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994;72:519–522.
- Nomura S. Functional and clinical significance of platelet- derived microparticles. Int J Haematol 2001;74:397–404.
- Nomura S, Suzuki M, Katsura K, et al. Platelet derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995;116:235–240. CrossRef
- Nomura S, Shouzu A, Omoto S, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998;80:388–392.
- Mattock MB, Barnes DJ, Viberti GC, et al. Microalbuninuria and coronary heart disease in non-insulin-dependent diabetes: An incidence study. Diabetes 1998;47:1786–1792.
- Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001; 357:1601–1608. CrossRef
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939–945. CrossRef
- Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40–49.
- Cheetham C, Collis J, O’Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin dependent diabetes. J Am Coll Cardiol 2000;36:1461–1466. CrossRef
- Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens 1999;17:447–452. CrossRef
- Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188–1192. CrossRef
- Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 2002;90:770–776. CrossRef
- Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521–527. CrossRef
- The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in diabetes. Hypertension 1994;23:145–158.
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert commitee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–1197.
- Investigative Committee on Guidelines for the Diagnosis and Treatment of Hyperlipidemia, Japan Atherosclerosis Society. Guidelines for the Diagnosis and Treatment of Hyperlipidemia in Adults. Doumyakukouka 1997;25:1–34.
- Murakami T, Komiyama Y, Masuda M, et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest 1996;26:996–1003. CrossRef
- Nomura S, Nakamura T, Cone J, Tandon NN, Kambayashi J. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry 2000;40:173–181. CrossRef
- Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant -containing microparticles. Blood 1996;88:3456–3464.
- Miyake T, Nomura S, Komiyama Y, et al.~Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Thromb Haemost 1997;78:902–909.
- Combes V, Simon A, Grau G, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104:93–102.
- Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8–19.
- Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988;263:18205–18212.
- Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayshi J. High shear stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001;158:277–287. CrossRef
- Lindholm LH, Ibsen H, Dahlof B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endopoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004–1010. CrossRef
- Kjeldsen SE, Dahlof B, Devereux RB, et al. LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endopoint Reduction (LIFE) substudy. JAMA 2002;288:1491–1498. CrossRef
- Shahinfar S, Dickson TZ, Ahmed T, et al. For the RENAAL Investigators. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL study. Kidney Int 2002;82(Suppl):64–67. CrossRef
- Wolf G, Schneider A, Helmchen U, Stahl RA. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998;6:112–120. CrossRef
- Hayek T, Aviram M, Heinrich R, Sakhnini E, Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem Biophys Res Commun 2000;273:417–420. CrossRef
- Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002;89:562–566. CrossRef
- Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952–959.
- Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/Paxillin phosphorylation of human monocytes. Hypertension 2001;37:587–593.
- Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hyper-cholesterolemia. J Am Coll Cardiol 2000;36:427–431. CrossRef
- Teupser D, Bruegel M, Stein O, Stein Y, Thiery J. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun 2001;289:838–844. CrossRef
- Serrano Jr CV, Yoshida VM, Venturinelli ML, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001;157:505–512. CrossRef
- Rezaie-Majd A, Maca T, Bucek RA, et al. Baghestanian. Simvastatin reduces expression of cytokines, interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194–1199. CrossRef
- Lefer DJ. Statins as potent antiinflammatory drugs. Circulation 2002;106:2041–2042. CrossRef
- Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation 2002; 106:1211–1218. CrossRef
- Cipollone F, Mezzetti A, Porreca E, et al. Davi. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia–-effects of statin therapy. Circulation 2002;106:399–402. CrossRef
- Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue–factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000;149:111–116. CrossRef
- Lee IT, Sheu WHH, Lin SY, Lee WJ, Song YM, Liu HC. Simvasatatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabet Complicat 2002;16:382–385. CrossRef
- Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days–-an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447–1452. CrossRef
- Tsakiris DA, Keller U, Zulewski H, Miserez AR, Wolf F, Marbet GA. Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein B. Eur J Clin Pharmacol 1997;53:277–279. CrossRef
- Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999;33:1286–1293. CrossRef
- Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 2002;22:1029–1035. CrossRef
- Zoja C, Corna D, Rottoli D, et al. Remuzzi. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635–1645. CrossRef
- Losartan and Simvastatin Inhibit Platelet Activation in Hypertensive Patients
Journal of Thrombosis and Thrombolysis
Volume 18, Issue 3 , pp 177-185
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- platelet activation markers
- hypertension hyperlipidemia
- type 2 diabetes mellitus
- Industry Sectors
- Author Affiliations
- 1. First Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
- 3. First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizonocho, Moriguchi, Osaka, 570-8507, Japan
- 2. Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan